Teva and mAbxience partner to develop biosimilar candidate for oncology

Teva Pharmaceuticals International and mAbxience have entered into a worldwide licencing agreement to develop an anti programmed cell death protein 1 oncology biosimilar candidate.

It is the second collaboration between the two entities, building on the partnership that began in April 2024. The new global licencing agreement aims to develop an additional oncology biosimilar, reinforcing the alliance between Teva and mAbxience.

By combining their expertise and resources, the companies are committed to fostering innovation and improving healthcare accessibility for patients globally.

The agreement grants Teva exclusive rights for several markets, including Europe and the US. It is in line with mAbxience’s strategy for expansion across the globe and reflects Teva’s efforts to grow its portfolio of biosimilars through strategic partnerships. As per the agreement, mAbxience will lead the development and manufacturing of the biosimilar, utilising its advanced certified good manufacturing practice-compliant (cGMP) facilities in Argentina and Spain.

Teva will be responsible for obtaining regulatory approvals and managing the commercialisation in the specified markets, aiming to provide access to this vital oncology treatment to patients worldwide.

Teva Pharmaceuticals has settled with the city of Baltimore in the US for $80m in September 2024, regarding its involvement in the opioid crisis. This settlement comes after Baltimore chose to opt out of a broader national case the previous year.